Polarean Imaging Plc (PLLWF)
OTC PINK OTC PINK Primary Summary
Polarean Imaging expands commercial arrangement with Ascend to 19 states
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has expanded its commercial agreement with Ascend Imaging, increasing coverage for its Xenon MRI platform from four to 19 US states. The company said the expanded arrangement will enhance sales efforts and strengthen access to healthcare institutions adopting functional lung imaging.
Polarean boost as analyst repeats 'buy' rating and 4p price target
Stifel on Monday reiterated its 'buy' rating on shares in Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) with a 4p price target, a significant premium to the current 0.46p valuation. The spur is progress at the University of Virginia Health, where Polarean has just signed a supply deal that will see the hospital fully equipped with clinical-grade “hyperpolarisers”.
Polarean Imaging lands latest contract in US, with University of Virginia Health
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has landed a new supply agreement with the University of Virginia Health, which is upgrading to complete the transition to full clinical Xenon MRI capabilities. The deal provides additional equipment for clinical use, following UVA's upgrade of two hyperpolariser systems last year.
Polarean Imaging Plc (PLLWF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Polarean Imaging Plc ever had a stock split?
Polarean Imaging Plc Profile
| Biotechnology Industry | Healthcare Sector | Christopher Richard Von Jako CEO | OTC PINK Exchange | GB00BF3DT583 ISIN |
| GB Country | 26 Employees | - Last Dividend | 16 Jul 2024 Last Split | - IPO Date |
Overview
Polarean Imaging plc is a distinctive entity in the medical imaging market, primarily focusing on the development, research, and commercialization of innovative imaging solutions. The company prides itself on offering a non-invasive and radiation-free functional imaging platform, setting it apart from conventional imaging technologies. Founded in 2016 and based in Durham, North Carolina, Polarean Imaging plc stands as a pioneering medical drug-device combination company. Its dedication to advancing medical imaging through groundbreaking research underlines its commitment to improving diagnostic methodologies without the drawbacks associated with traditional imaging techniques.
Products and Services
- HPX Hyperpolarizer
A core product in Polarean's arsenal, the HPX Hyperpolarizer, revolutionizes the generation of hyperpolarized gases. This advanced technology enhances the signal strength of gases used in magnetic resonance imaging (MRI) scans, significantly improving image quality and enabling detailed pulmonary imaging.
- HPX Measurement Station
Designed to complement the HPX Hyperpolarizer, this measurement station facilitates the precise quantification and analysis of hyperpolarized gases. It's an essential tool for researchers and clinicians aiming to exploit the full capabilities of hyperpolarized gas MRI technology for lung imaging and beyond.
- HPX Gas Manifold
An integral component of Polarean’s imaging system, the HPX Gas Manifold ensures the safe and efficient delivery of hyperpolarized gases to the MRI scanning system. This device plays a critical role in maintaining the integrity and performance of the imaging process.
- Chest Coil
Specially designed for pulmonary imaging, the Chest Coil is optimized for use with Polarean’s imaging platform. It enhances the reception of MRI signals, thereby improving the clarity and detail of lung images captured using hyperpolarized gas technology.
- Dose Delivery Bags
These bags are designed for the secure and effective delivery of hyperpolarized gases to patients during MRI scans. They are a crucial part of Polarean’s non-invasive imaging solution, ensuring that patients receive the correct dosage in a controlled manner.
